Lactose (India)
BSE: LACTOSE · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Lactose (India)'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Lactose (India) Limited is a Mumbai-based pharmaceutical company specialising in the manufacture of lactose monohydrate and various pharmaceutical excipients. The company also produces liquid and dry food supplements, prebiotic ingredients, and pharmaceutical formulations for domestic and international markets.
Business Model
The company generates revenue through the production and sale of pharmaceutical-grade excipients and nutraceutical ingredients. It leverages its WHO-GMP certified manufacturing facility in Gujarat to provide contract manufacturing services to global healthcare brands.
Growth Outlook
Growth is driven by the expansion of its contract manufacturing services and the increasing demand for high-quality pharmaceutical excipients and prebiotic ingredients. The company continues to leverage its quality certifications to penetrate international markets further.
Key Risks
- Regulatory Compliance. The company faces risks related to maintaining stringent WHO-GMP certifications required for international export operations.
- Raw Material Price Volatility. Fluctuations in the cost of raw materials used in the production of lactose and food supplements can impact profit margins.
- Competitive Market. The pharmaceutical excipient sector is highly competitive, requiring continuous investment in quality and production efficiency to maintain market share.
Start your research today
Unlock AI insights, financials, peers and live data on Lactose (India) and 5,000+ companies — free.
Key Metrics
REVENUE
₹163 Cr
TTM · standalone
NET PROFIT
₹6 Cr
TTM · standalone
EPS
₹4.81
TTM · standalone
RETURN ON EQUITY
10.1%
TTM · standalone
P/E
21.4x
Q4 FY26 · standalone
EV/EBITDA
8.6x
Q4 FY26 · standalone
EBITDA MARGIN
11.9%
TTM · standalone
NET PROFIT MARGIN
4.1%
Q4 FY26 · standalone
DEBT TO EQUITY
0.9x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Lactose (India)LACTOSE | ₹132 Cr | 21.84 | 9.95 | 40.3% | 11.9% | 10.1% | 15.3% | -6.2% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Q4 FY26
Financials
Lactose (India)
BSE: LACTOSE · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Lactose (India)'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Lactose (India) Limited is a Mumbai-based pharmaceutical company specialising in the manufacture of lactose monohydrate and various pharmaceutical excipients. The company also produces liquid and dry food supplements, prebiotic ingredients, and pharmaceutical formulations for domestic and international markets.
Business Model
The company generates revenue through the production and sale of pharmaceutical-grade excipients and nutraceutical ingredients. It leverages its WHO-GMP certified manufacturing facility in Gujarat to provide contract manufacturing services to global healthcare brands.
Growth Outlook
Growth is driven by the expansion of its contract manufacturing services and the increasing demand for high-quality pharmaceutical excipients and prebiotic ingredients. The company continues to leverage its quality certifications to penetrate international markets further.
Key Risks
- Regulatory Compliance. The company faces risks related to maintaining stringent WHO-GMP certifications required for international export operations.
- Raw Material Price Volatility. Fluctuations in the cost of raw materials used in the production of lactose and food supplements can impact profit margins.
- Competitive Market. The pharmaceutical excipient sector is highly competitive, requiring continuous investment in quality and production efficiency to maintain market share.
Start your research today
Unlock AI insights, financials, peers and live data on Lactose (India) and 5,000+ companies — free.
Key Metrics
REVENUE
₹163 Cr
TTM · standalone
NET PROFIT
₹6 Cr
TTM · standalone
EPS
₹4.81
TTM · standalone
RETURN ON EQUITY
10.1%
TTM · standalone
P/E
21.4x
Q4 FY26 · standalone
EV/EBITDA
8.6x
Q4 FY26 · standalone
EBITDA MARGIN
11.9%
TTM · standalone
NET PROFIT MARGIN
4.1%
Q4 FY26 · standalone
DEBT TO EQUITY
0.9x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q4 FY26